Pacira BioSciences/$PCRX
1D1W1MYTD1Y5YMAX
Capital at risk
About Pacira BioSciences
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
- Ticker
- $PCRX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 827
- Headquarters
- Brisbane, United States
- Website
- www.pacira.com
PCRX Metrics
BasicAdvanced
$1B
71.53
$0.35
0.27
-
Price and volume
Market cap
$1B
Beta
0.27
52-week high
$27.66
52-week low
$18.80
Average daily volume
639K
Financial strength
Current ratio
5.042
Quick ratio
3.213
Long term debt to equity
59.797
Total debt to equity
61.329
Interest coverage (TTM)
2.12%
Profitability
EBITDA (TTM)
123.966
Gross margin (TTM)
79.21%
Net profit margin (TTM)
1.96%
Operating margin (TTM)
4.40%
Effective tax rate (TTM)
17.06%
Revenue per employee (TTM)
$900,000
Management effectiveness
Return on assets (TTM)
1.48%
Return on equity (TTM)
2.05%
Valuation
Price to earnings (TTM)
71.525
Price to revenue (TTM)
1.403
Price to book
1.49
Price to tangible book (TTM)
2.73
Price to free cash flow (TTM)
5.832
Free cash flow yield (TTM)
17.15%
Free cash flow per share (TTM)
4.314
Growth
Revenue change (TTM)
5.71%
Earnings per share change (TTM)
-112.53%
3-year revenue growth (CAGR)
3.69%
10-year revenue growth (CAGR)
10.84%
3-year earnings per share growth (CAGR)
32.53%
10-year earnings per share growth (CAGR)
1.30%
What the Analysts think about PCRX
Analyst ratings (Buy, Hold, Sell) for Pacira BioSciences stock.
Analyst projections of the future price of Pacira BioSciences stock.
Bulls say / Bears say
Second quarter 2026 revenues rose 6 percent year-over-year to $192.4 million, driven by growth across EXPAREL, ZILRETTA, and iovera°, reflecting resilient demand for its non-opioid portfolio (Pacira SEC Q2 2026 Results).
UnitedHealthcare began providing separate reimbursement for EXPAREL in outpatient settings covering approximately 40 million members, enhancing access and supporting higher-margin sales outside the surgical bundle (Pacira SEC Q2 2026 Results).
Pacira published positive two-year Phase 1 results for PCRX-201 in the Annals of the Rheumatic Diseases, demonstrating sustained safety and efficacy in knee osteoarthritis and strengthening confidence in its gene therapy platform (Pacira Investor Release).
Pacira lowered its full‐year 2026 revenue guidance to $735 million–$760 million from $745 million–$770 million following the divestiture of iovera°, reducing midpoint revenue expectations by $10 million (EveryTicker).
Adjusted EBITDA decreased to $48.7 million in Q2 2026 from $54.3 million in Q2 2025, underscoring margin pressure from contract mix shifts and expanded SG&A spending (Pacira SEC Q2 2026 Results).
Key Phase 2 ASCEND data for PCRX-201 will not be available until late 2026, extending development timelines and delaying potential regulatory filings and commercialization milestones (Pacira SEC Q2 2026 Results).
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2026.
PCRX Financial Performance
Revenues and expenses
PCRX Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing PCRX
AllUSDGBPEUR
Fund name | Fund size | $PCRX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.07% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.07% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.06% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.06% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.